Story thread · 6 reports / 6 sources
Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio
cnbc.com · 5h
How the coverage leans
Across 6 sources · syndicated copies counted once
Jazz Pharmaceuticals will acquire Actio Biosciences, Inc., a deal that expands Jazz's pipeline and presence in rare epilepsy treatments.
First report: Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal — finance.yahoo.com, 1d
The coverage
- Jazz Pharma Expands Again in Epilepsy With $850M Actio Bio Acquisition
medcitynews.com · 22h
- Jazz bets on epilepsy again by acquiring Actio for $820M upfront
endpts.com · 1d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.